Newsbriefs ----------------------------------------------------------------- Glendening budget increases aid to private higher education ----------------------------------------------------------------- Gov. Parris N. Glendening's 1996 budget proposal calls for a $34 million, or 4.6 percent, increase over last year in state aid for higher education. Included in his proposal is a total of $28.4 million in aid to Hopkins and other private institutions under the Sellinger Program of Aid to Independent Colleges and Universities. This amount will be reduced by $1.2 million if special legislation is enacted altering the program's formula. The budget also proposes to fully fund the special state operating grant of $2.995 million for the Peabody Institute. The governor's proposed capital budget of $158.9 million for projects at all colleges and universities allocates $8.3 million for building projects at independent colleges and universities. Of that amount, $2.8 million is targeted for renovations for the Milton S. Eisenhower Library on the Homewood campus and $2 million for the Peabody Art Fund. The art fund, which is expected to total $15 million by June 30, 1996, will be transferred to the Peabody Institute in exchange for the art collection at the end of FY1996, in accordance with a statutory agreement between the university and the state. ----------------------------------------------------------------- Timing of immune responses affects development of AIDS ----------------------------------------------------------------- Hopkins researchers say that gay men infected with the AIDS virus remain free of AIDS symptoms for at least six years if they make large amounts of antibodies against some parts of the virus during the first few months after infection. Infected gay men who mount weaker immune responses during this time tend to develop AIDS much faster, within three years. The findings should help physicians to identify which men may need treatment soon and which men probably will not develop symptoms for many years, said Homayoon Farzedegan, associate professor of infectious disease epidemiology at the School of Public Health and lead author of the study. "The unique thing about this study is that it's the first time that so many HIV-positive men who progressed rapidly to AIDS have been followed so closely for so long after they first seroconverted," Dr. Farzedegan said. Seroconversion, he explained, occurs when antibodies to the AIDS virus appear in the person's blood and is the primary evidence of infection. The 10-year study compared 17 newly infected men who progressed rapidly to AIDS with a control group of 42 newly infected men who had not developed AIDS after six years. Men who developed AIDS within three years of becoming infected had more of the virus's genetic material in their blood than did men who did not progress rapidly to AIDS. And in men who developed AIDS faster, the immune system cells called T cells, which help to fight germs, were less active against infections than in the control group. ----------------------------------------------------------------- First effective drug developed for treatment of sickle cell ----------------------------------------------------------------- A Hopkins-led team of researchers last week announced the first effective treatment for the most painful symptoms of sickle cell anemia, an inherited blood disease affecting about 72,000 Americans. Physicians say that the disease, which most commonly affects people whose ancestors are from Africa, the Middle East, the Mediterranean basin and India, shortens the lives of its victims by approximately 30 years. The researchers, led by Samuel Charache, professor of medicine, cautioned that the drug, hydroxyurea, is not a cure and that researchers do not know whether it can be used in children or pregnant women. For about 15 percent of those diagnosed with sickle cell anemia, the drug could slowly turn their lives around. Until now, people who suffered from severe cases either took pain medications or had blood transfusions. The research, which began with two Baltimore men 12 years ago and was recently replicated in a national study, showed that daily doses of hydroxyurea reduced by 50 percent the frequency of painful episodes, hospitalizations, transfusions and a life-threatening chest syndrome. Researchers said the drug works by turning on a switch that stimulates the production of fetal hemoglobin, which interferes with the blood damaging process. Hydroxyurea, which can be prescribed for sickle cell patients, has yet to be approved by the U.S. Food and Drug Administration. ----------------------------------------------------------------- Hopkins Oncology Center joins Comprehensive Cancer Network ----------------------------------------------------------------- The Johns Hopkins Oncology Center has joined 12 of the country's leading cancer centers to form the National Comprehensive Cancer Network, which will develop practice standards and outcomes measures to promote high-quality, cost-effective care for cancer patients. "The alliance of the top cancer providers in the nation... promises to be a major force in shaping the future of the delivery of care for cancer patients in this country," said Martin D. Abeloff, the Oncology Center director. Individual centers will evaluate and refine their own operations to serve as models for the nation. Members also will work closely within their regions and through their own affiliations to raise standards for care in the community. ----------------------------------------------------------------- Proteins may help sperm 'sniff' their way to eggs ----------------------------------------------------------------- A Hopkins study asserts sperm in mammals may "sniff" their way to the egg by using the same types of proteins the nose uses to sense odors. If confirmed, the new findings could lead to treatments for contraception that make it harder for sperm to "smell" and find the egg, as well as infertility treatments that improve the sperm's capacity to home in on the egg's signal. The study, reported in the January issue of Molecular Medicine, showed that a part of sperm tails in rats contains the same type of receptor proteins that appear in the nose. These proteins respond to airborne molecules that enter the nose, triggering a reaction that sends a signal to the brain. Scientists think a similar reaction may be triggered when receptor proteins in sperm encounter molecules released by the egg. This reaction may regulate the way a sperm swims. "The next step is to see if researchers can find a molecule from the egg that acts as a signal to sperm," said the report's lead author, Hopkins medical and doctoral student Loren Walensky. "It's already been shown that sperm swim toward the follicular fluid, the fluid that surrounds the egg, so that's the first place to look." Walensky, who works in the laboratory of Solomon Snyder, director of Neuroscience, found another strong similarity between sperm and the olfactory system: two proteins that turn down the signal from olfactory receptors are also present on the same portion of the sperm tail. "These similarities make us hopeful that what we'll learn from sperm receptors and egg signaling may help us better understand the sense of smell," Walensky said.